TY - JOUR
T1 - Potential effects of CRM1 inhibition in mantle cell lymphoma
AU - Zhang, Ke Jie
AU - Wang, Michael
N1 - Funding Information:
We would like to thank Joe Munch in MD Anderson’s Department of Scientific Publications for editing the manuscript. Disclosure: The authors indicated no potential conflicts of interest. This work was supported in part by grants from Fujian Provincial Department of Science &Technology (2009-CXB-57/ 2011J01252) and Bureau of Science & Technology of Xiamen, China (3502Z20094012).
PY - 2012/12
Y1 - 2012/12
N2 - Mantle cell lymphoma (MCL) is an aggressive histotype of B-cell non-Hodgkin lymphoma. The disease has no known cure, which prompts the urgent need for novel therapeutic agents. Chromosomal region maintenance 1 (CRM1) may play a role in human neoplasia and serve as a novel target of cancer treatment. This study summarizes MCL pathogenesis and determines the involvement of CRM1 in the regulation of several vital signaling pathways contributing to MCL pathogenesis, including the pathways of cell cycle progression, DNA damage response, phosphoinositide kinase-3, nuclear factor-κB activation, and chromosomal stability. A preclinical study is also presented to compare the CRM1 status in MCL cell lines and primary MCL cells with normal B cells, as well as the therapeutic efficiency of CRM1 inhibition in MCL in vitro and in vivo, which make these agents potential targets of novel MCL treatments.
AB - Mantle cell lymphoma (MCL) is an aggressive histotype of B-cell non-Hodgkin lymphoma. The disease has no known cure, which prompts the urgent need for novel therapeutic agents. Chromosomal region maintenance 1 (CRM1) may play a role in human neoplasia and serve as a novel target of cancer treatment. This study summarizes MCL pathogenesis and determines the involvement of CRM1 in the regulation of several vital signaling pathways contributing to MCL pathogenesis, including the pathways of cell cycle progression, DNA damage response, phosphoinositide kinase-3, nuclear factor-κB activation, and chromosomal stability. A preclinical study is also presented to compare the CRM1 status in MCL cell lines and primary MCL cells with normal B cells, as well as the therapeutic efficiency of CRM1 inhibition in MCL in vitro and in vivo, which make these agents potential targets of novel MCL treatments.
KW - CRM1 inhibitor
KW - Chromosomal region maintenance 1 (CRM1)
KW - mantle cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84875413192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875413192&partnerID=8YFLogxK
U2 - 10.1007/s11670-012-0278-5
DO - 10.1007/s11670-012-0278-5
M3 - Review article
AN - SCOPUS:84875413192
SN - 1000-9604
VL - 24
SP - 374
EP - 387
JO - Chinese Journal of Cancer Research
JF - Chinese Journal of Cancer Research
IS - 4
ER -